Search Results - "Muduma, Gorden"

Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant by Muduma, Gorden, Saunders, Rhodri, Odeyemi, Isaac, Pollock, Richard F

“…Several meta-analyses comparing ciclosporin with tacrolimus have been conducted since the 1994 publication of the tacrolimus registration trials, but most…”
Get full text

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland by Pollock, Richard F, Muduma, Gorden

“…Iron deficiency anemia (IDA) is a common sequela of inflammatory bowel disease (IBD), arising from the combined effects of gastrointestinal blood loss and…”
Get full text

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000 by Pollock, Richard F, Muduma, Gorden

“…The reported prevalence of iron deficiency anemia (IDA) varies widely but estimates suggest that 3% of men and 8% of women have IDA in the UK. Parenteral iron…”
Get full text

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence by Muduma, Gorden, Odeyemi, Isaac, Smith-Palmer, Jayne, Pollock, Richard F

“…Advagraf is a once-daily prolonged-release formulation of tacrolimus with proven noninferiority to Prograf, a twice-daily immediate-release formulation of…”
Get full text

A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom by Pollock, Richard F, Muduma, Gorden

“…Intravenous iron is the recommended treatment for patients with iron deficiency anemia (IDA) where oral iron is ineffective or rapid iron replenishment is…”
Get more information

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment by Pollock, Richard F, Muduma, Gorden

“…The efficacy of oral iron in treating iron deficiency anemia (IDA) can be limited by poor gastrointestinal (GI) absorption and adverse GI symptoms; intravenous…”
Get more information

An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark by Pollock, Richard F., Muduma, Gorden

“…Introduction The incidence of inflammatory bowel disease (IBD) in Denmark is among the highest in the world, with Crohn’s disease and ulcerative colitis…”
Get full text

Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland by Loughnane, Frank, Muduma, Gorden, Pollock, Richard F.

“…Introduction Intravenous (IV) iron is typically the preferred treatment for patients with iron deficiency anemia (IDA) who cannot tolerate or absorb oral iron,…”
Get full text

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark by Pollock, Richard F., Muduma, Gorden

Get full text

Clinical and economic impact of immunosuppressive therapy in the treatment and management of adult renal and liver transplantation by Muduma, Gorden

“…World wide the number of people living with renal or liver transplants is growing due to the increase in prevalence of end stage renal disease and end stage…”
Get full text

A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK by Muduma, Gorden, Odeyemi, Isaac, Pollock, Richard F

“…Calcineurin inhibitors (CNIs) represent the cornerstone of immunosuppressive therapy after liver transplantation. A recent network meta-analysis (NMA)…”
Get more information

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients by Muduma, Gorden, Odeyemi, Isaac, Smith-Palmer, Jayne, Pollock, Richard F.

“…Antibody-mediated rejection (AbMR) is a leading cause of late graft loss in kidney transplant recipients, accounting for up to 60% of late graft failures. AbMR…”
Get full text

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice by Muduma, Gorden, Odeyemi, Isaac, Pollock, Richard Fulton

“…Background As of 2014, there were approximately 8300 patients with a functioning liver transplant in the UK Transplant Registry, with 880 liver transplants…”
Get full text

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice by Muduma, Gorden, Odeyemi, Isaac, Pollock, Richard Fulton

Get full text

The Last Year Before Graft Failure Negatively Impacts Economic Outcomes and is Associated With Greater Healthcare Resource Utilization Compared With Previous Years in the United Kingdom: Results of a Retrospective Observational Study by Muduma, Gorden, Aluvihare, Varuna, Clancy, Marc, de Nigris, Enrico, Whitlock, Carolyn, Landeira, Margarita, Nazir, Jameel

“…Kidney and liver transplantation is the standard of care for end-stage renal or liver disease. However, long-term survival of kidney and liver grafts remain…”
Get full text

A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability by Muduma, Gorden, Odeyemi, Isaac, Pollock, Richard F

“…Randomized controlled trials have shown that a once-daily prolonged-release (PR) tacrolimus formulation (PR tacrolimus; Advagraf * ), is non-inferior to a…”
Get more information

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients by Muduma, Gorden, Shupo, Francis C, Dam, Sophie, Hawken, Natalia A, Aballéa, Samuel, Odeyemi, Isaac, Toumi, Mondher

“…Renal transplantation (RT) is considered the treatment of choice for end-stage renal disease compared to dialysis, offering better health-related quality of…”
Get full text

Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales by Muduma, Gorden, Shaw, Jane, Hart, Warren M, Odeyemi, Abayomi, Odeyemi, Isaac

“…End-stage renal disease is the irreversible final stage of chronic kidney disease and is fatal when not managed by either transplantation or dialysis…”
Get full text